Lv11
18 积分 2024-03-07 加入
177a: FIRST-IN-CLASS ORAL TL1A NANOBODY AND LONG-ACTING TL1A/IL-23 BISPECIFIC NANOBODY: NOVEL THERAPIES FOR INFLAMMATORY BOWEL DISEASE
2小时前
求助中
Anti-TL1A antibody, afimkibart, in moderately-to-severely active ulcerative colitis (TUSCANY-2): a multicentre, double-blind, treat-through, multi-dose, randomised, placebo-controlled, phase 2b trial
2天前
已完结
Humoral determinants of checkpoint immunotherapy
22天前
已完结
177a: FIRST-IN-CLASS ORAL TL1A NANOBODY AND LONG-ACTING TL1A/IL-23 BISPECIFIC NANOBODY: NOVEL THERAPIES FOR INFLAMMATORY BOWEL DISEASE
1个月前
已关闭
Transcriptome-Based Network Analysis Reveals a Spectrum Model of Human Macrophage Activation
1个月前
已完结
CTLA-4-expressing ILC3s restrain interleukin-23-mediated inflammation
2个月前
已完结
Sirpα on tumor-associated myeloid cells restrains antitumor immunity in colorectal cancer independent of its interaction with CD47
2个月前
已完结
Guselkumab plus golimumab combination therapy versus guselkumab or golimumab monotherapy in patients with ulcerative colitis (VEGA): a randomised, double-blind, controlled, phase 2, proof-of-concept trial
3个月前
已完结
Combination therapy blocking TNF superfamily members 14 and 15 reverses pulmonary fibrosis
4个月前
已关闭
P1114 Engineering and Development of a Novel Bispecific Antibody Targeting IL-23 and TL1A
5个月前
已关闭
皖公网安备34019202002308
